AMA votes to require disclosure of drug prices in DTC ads

AMA votes to require disclosure of drug prices in DTC ads

The association also recommended that the Centers for Medicare and Medicaid Services negotiate drug prices.

Bayer aims to drive patient-HCP dialogue with data-sharing app for MS

Bayer aims to drive patient-HCP dialogue with data-sharing app for MS

The FDA-approved app will allow MS patients to share their medication injection history with HCPs.

Half of clinical-trial sites offer free transportation to patients

Half of clinical-trial sites offer free transportation to patients

Consent forms and reimbursement are the main deterrents of offering the service.

Five things for pharma marketers to know: Wednesday, June 14, 2017

Five things for pharma marketers to know: Wednesday, June 14, 2017

Sanofi to boost investment in biologics R&D; Sage's awareness campaign criticized; PatientsLikeMe poll finds 95% of patients want some costs of drugs covered

Five things for pharma marketers to know: Tuesday, June 13, 2017

Five things for pharma marketers to know: Tuesday, June 13, 2017

Alkermes lobbies lawmakers on its opioid addiction drug; rep salaries rise; SCOTUS rules in favor of Sandoz in biosimilar suit

Roundtable: When it comes to media, pharma compares the new with the old

Roundtable: When it comes to media, pharma compares the new with the old

In apportioning their media budgets, pharma companies continue to straddle the line between new and traditional strategies.

Five things for pharma marketers to know: Monday, June 12, 2017

Five things for pharma marketers to know: Monday, June 12, 2017

Teva gets FDA approval for Truvada generic; the FDA rejects Coherus' Neulasta biosimilar; only 17% of Americans find health industries to be innovative

Healthcare brands turn to emotion, to better tell their stories

Healthcare brands turn to emotion, to better tell their stories

It's never been easy for pharmaceutical companies or healthcare brands to authentically engage with patients or with doctors.

How Dana Maiman does Cannes

How Dana Maiman does Cannes

The CEO of FCB Health shares her gelato secrets and talks about why this year is truly the year of healthcare.

How Graham Mills does Cannes

How Graham Mills does Cannes

He buys macarons to make friends and finds that Cannes is an "extraordinary opportunity to rewire your brain."

How Ritesh Patel does Cannes

How Ritesh Patel does Cannes

Words of the wise: Vacant the Gutter Bar by 2 a.m., and make sure to bring flip flops and go walk on the beach.

Astellas reprimanded by U.K. drug regulator

Astellas reprimanded by U.K. drug regulator

The drugmaker has been handed a "public reprimand" by the U.K.'s Prescription Medicines Code of Practice Authority after the creative director of an unnamed agency used the company's patient support materials on its website.

Five things for pharma marketers to know: Friday, June 9, 2017

Five things for pharma marketers to know: Friday, June 9, 2017

The FDA asks Endo to take opioid off the market; Lilly partners with Swiss biotech; House committee advances PDUFA bill — without off-label provision

Live @ the MM&M Hall of Femme: Women talk about taking action to bridge the gender gap

Live @ the MM&M Hall of Femme: Women talk about taking action to bridge the gender gap

Executives discussed the challenges and opportunities they have faced as women.

Five things for pharma marketers to know: Thursday, June 8, 2017

Five things for pharma marketers to know: Thursday, June 8, 2017

Novartis CAR-T drug boasts competitive response rates; WPP reports slowing sales for healthcare business; AZ sells migraine drug

How should pharma market to millennials?

How should pharma market to millennials?

The opportunity to reach the millennial audience is great, and there's a lot that brands can do now to ensure that companies stay relevant to Gen Y cultural trends.

Five things for pharma marketers to know: Wednesday, June 7, 2017

Five things for pharma marketers to know: Wednesday, June 7, 2017

Pfizer receives breakthrough designation for experimental rare disease drug; Endocyte cuts 30 jobs; AbbVie RA drug meets Phase-III goals

PDUFA amendment would broaden off-label rules

PDUFA amendment would broaden off-label rules

The bill, introduced in March, is being considered as an amendment in the upcoming PDUFA reauthorization legislation.

23andMe partners with 'Despicable Me 3' for first movie partnership

23andMe partners with 'Despicable Me 3' for first movie partnership

The genetics testing company helps Gru find his lost-lost brother in six-week marketing push.

Voice assistants may ease EHR burden for docs, but challenges exist

Voice assistants may ease EHR burden for docs, but challenges exist

With physicians spending nearly four hours a day on their electronic health records, experts say voice assistants could help reduce their workload one day.

Five things for pharma marketers to know: Tuesday, June 6, 2017

Five things for pharma marketers to know: Tuesday, June 6, 2017

Pfizer increased drug prices by 20% in 2017; Perrigo CEO to retire; MannKind sponsors reality TV show to promote Afrezza

Physicians call for DTC ads to include retail prices

Physicians call for DTC ads to include retail prices

They are asking the American Medical Association to support the policy proposal.

Sunday at ASCO: What the latest trial data has to say about precision medicine

Sunday at ASCO: What the latest trial data has to say about precision medicine

Notably, data for AstraZeneca's Lynparza, Johnson & Johnson's Zytiga, and Loxo Oncology's larotrectinib highlights the move toward specialized medicine.

Five things for pharma marketers to know: Monday, June 5, 2017

Five things for pharma marketers to know: Monday, June 5, 2017

Medicare beneficiaries struggle to pay for COPD inhalers; Novartis partners with IBM Watson Health; Mylan hasn't lowered EpiPen prices

Saturday at ASCO: Trial results reveal promising data for combo I-O drugs but no home runs

Saturday at ASCO: Trial results reveal promising data for combo I-O drugs but no home runs

Putting aside the hype around combination immunotherapies, concerns remain about overall response rates for these drugs.

Why Novartis' Shah-Mehta chose a career in pharma sales

Why Novartis' Shah-Mehta chose a career in pharma sales

The executive director of oncology marketing is fascinated by the resilience of the human body.

Five things for pharma marketers to know: Friday, June 2, 2017

Five things for pharma marketers to know: Friday, June 2, 2017

Oncologists more likely to prescribe drugs when receiving travel, meal payments; Tesaro reportedly considering a sale; AbbVie has best pharma reputation

Roundtable: Social centricity in oncology

Roundtable: Social centricity in oncology

Industry leaders discussed why a social-centric approach is especially important in oncology, particularly as it relates to health systems, interactions with healthcare providers, and family support.

Five things for pharma marketers to know: Thursday, June 1, 2017

Five things for pharma marketers to know: Thursday, June 1, 2017

50% of consumers say they will share their health data with tech giants; pharma CEOs expect pricing proposal from Trump administration; FDA approves generic versions of Strattera

The immuno-oncology market prepares for the inevitable question: 'What's next?'

The immuno-oncology market prepares for the inevitable question: 'What's next?'

This includes concerns about the effectiveness — and cost-effectiveness — of drugs like Merck's Keytruda and Bristol-Myers Squibb's Opdivo, in combination or alone.

Five things for pharma marketers to know: Wednesday, May 31, 2017

Five things for pharma marketers to know: Wednesday, May 31, 2017

BMS partners on Opdivo combo; one-quarter of insurers have signed an outcomes-based contract with a drugmaker; rebates do not lead to savings for Medicare beneficiaries

Outcome Health raises $500 million in financing round

Outcome Health raises $500 million in financing round

The deal highlights ongoing interest in the influential point-of-care market.

Five things for pharma marketers to know: Tuesday, May 30, 2017

Five things for pharma marketers to know: Tuesday, May 30, 2017

Harvard Pilgrim signs two outcomes contracts with AstraZeneca; lobbyists fight over drug-pricing proposals; docs say no to adult ADHD screening test

Advocacy groups add a shade of resistance to Pride celebrations

Advocacy groups add a shade of resistance to Pride celebrations

The tone has changed dramatically since last year for LGBT rights groups, which are now as focused on opposing the Trump administration's policies as celebrating progress and community.

2017 Pharma Report: All the data in one place

2017 Pharma Report: All the data in one place

Find data on patent expirations, new drug approvals, top therapeutic classes, and top-selling drugs.

Pricing pressure is the new new normal for drugmakers

Pricing pressure is the new new normal for drugmakers

Drug prices, as you may have heard, are kind of high. But price growth has slowed after sharp spikes in 2014 and 2015.

Five things for pharma marketers to know: Friday, May 26, 2017

Five things for pharma marketers to know: Friday, May 26, 2017

FDA presents ideas to tackle drug prices; patients aware of side effects more likely to report them; scientists use Apple's Research Kit for clinical purposes

Following Tymlos approval, Radius uses Facebook to educate about osteoporosis

Following Tymlos approval, Radius uses Facebook to educate about osteoporosis

The company said adult women between the ages of 50 and 70 are most likely to share content on the social media platform.

Five things for pharma marketers to know: Thursday, May 25, 2017

Five things for pharma marketers to know: Thursday, May 25, 2017

Fitness trackers do not reliably track calories, docs find; health-tech startups face market uncertainty; FDA adcom votes in favor of Puma breast-cancer drug

Twitter launches DM cards for brands

Twitter launches DM cards for brands

Twitter has launched a customizable Direct Message Card that brands can use to promote and share the bots or other customer experiences they've created, while Snapchat and Instagram have launched stories updates.

Five things for pharma marketers to know: Wednesday, May 24, 2017

Five things for pharma marketers to know: Wednesday, May 24, 2017

Keytruda receives first approval based on a genetic feature and not tumor's location; Alexion reps reportedly crossed ethical lines; profits up at insurers

The FDA cites risk info in letter over Contrave DTC ad

The FDA cites risk info in letter over Contrave DTC ad

The regulator also took issue with how Orexigen Therapeutics presented the risk information

Nearly every $100,000 drug approved in the last three years was for a rare disease

Nearly every $100,000 drug approved in the last three years was for a rare disease

This includes Sarepta Therapeutics' Exondys 5 and Vertex Pharmaceuticals' Orkambi.

Alexion hires new chief commercial officer

Alexion hires new chief commercial officer

Brian Goff is expected to replace Carsten Thiel in June. The drugmaker said Tuesday that Thiel along with several other execs would be leaving the firm.

Otsuka, Proteus refile their sensor-enabled drug

Otsuka, Proteus refile their sensor-enabled drug

The chip-in-a-pill combines antipsychotic Abilify with an ingestible sensor made by Proteus.

The class of 2017 wants it all: Work-life balance and a well-paid future

The class of 2017 wants it all: Work-life balance and a well-paid future

Recent grads aren't afraid to voice their expectations, and agencies are responding with new programs and policies.

The FDA says Puma's breast-cancer drug is effective, cautions about side effects

The FDA says Puma's breast-cancer drug is effective, cautions about side effects

An FDA advisory committee is expected to decide Wednesday whether to recommend neratinib for approval.

Five things for pharma marketers to know: Tuesday, May 23, 2017

Five things for pharma marketers to know: Tuesday, May 23, 2017

Disease awareness ads can boost drug sales; AstraZeneca's experimental asthma drug cuts steroid use; FDA approves Regeneron and Sanofi's RA drug

Five things for pharma marketers to know: Monday, May 22, 2017

Five things for pharma marketers to know: Monday, May 22, 2017

Amgen's osteoporosis drug set back by safety issue; new FDA digital biz to hire 13 engineers; Celgene's MS drug bests Avonex in trial

Apple helps a blind drummer and nonverbal teen thrive in new spots

Apple helps a blind drummer and nonverbal teen thrive in new spots

Siri and accessibility features take center stage in ads for Global Accessibility Awareness Day.

Expert Q&A: Getting patient centricity right

Expert Q&A: Getting patient centricity right

Five sector pros discuss adapting to patient-centricity and how pinpointing patient needs leads to success.

Five things for pharma marketers to know: Friday, May 19, 2017

Five things for pharma marketers to know: Friday, May 19, 2017

Keytruda gets two new FDA approvals; lawmakers aim to speed up approval of generics; Incyte uses soap opera to spread rare-disease awareness

Read the complete May 2017 digital edition

Read the complete May 2017 digital edition

Here you'll find everything from our May 2017 issue, including our Top 40 Transformers, deep dive into autoimmune drugs, and more.

Study: One-third of docs trust pharma content on HCP sites

Study: One-third of docs trust pharma content on HCP sites

In general, physicians believe that information provided by pharma companies is difficult to find and lacking in science.

Five things for pharma marketers to know: Thursday, May 18, 2017

Five things for pharma marketers to know: Thursday, May 18, 2017

Docs spend little time telling patients about cancer costs; Shire to file hereditary angioedema drug with the FDA by 2018; Philips CEO on access obstacles

Califf joins Verily, to help the firm address the needs of doctors

Califf joins Verily, to help the firm address the needs of doctors

Robert Califf stepped down from his role as FDA commissioner in January.

Five things for pharma marketers to know: Wednesday, May 17, 2017

Five things for pharma marketers to know: Wednesday, May 17, 2017

FDA requires boxed warning for J&J's Invokana; Amazon to reportedly hire GM to enter pharmacy industry; WannCry ransomware affects some health organizations

What marketers need to know about tax reform, off-label promotion, pricing

What marketers need to know about tax reform, off-label promotion, pricing

The ad-tax deduction is likely once again on the table.

Five things for pharma marketers to know: Tuesday, May 16, 2017

Five things for pharma marketers to know: Tuesday, May 16, 2017

A New York county sues drugmakers over opioid marketing; AstraZeneca files suit against GSK exec; Thermo Fisher acquires biologics firms

Califf calls for marketers to develop off-label 'code of ethics'

Califf calls for marketers to develop off-label 'code of ethics'

The former FDA commissioner said marketers need to focus on ensuring that off-label promotion is "non-misleading."

Infographic: The battle for medication adherence

Infographic: The battle for medication adherence

Drugmakers and providers alike struggle to find the best tools, words, and technologies that will improve adherence rates among patients with chronic diseases.

Five things for pharma marketers to know: Monday, May 15, 2017

Five things for pharma marketers to know: Monday, May 15, 2017

Funding for patient-assistance charities makes up 7% of operating expenses for drugmakers; Avanir ad under fire; Trump to consider Medicare rebates

Back at Dendreon, Caggiano takes on Provenge's comeback

Back at Dendreon, Caggiano takes on Provenge's comeback

Jim Caggiano had witnessed Provenge's birth during an earlier turn at Dendreon and couldn't understand what went wrong.

Mother New York fills resume gaps with 'The Pregnancy Pause'

Mother New York fills resume gaps with 'The Pregnancy Pause'

For Mother's Day, the agency gives job-hunters a way to proudly display maternity leave as a full-time job.

Five things for pharma marketers to know: Friday, May 12, 2017

Five things for pharma marketers to know: Friday, May 12, 2017

AstraZeneca's Imfinzi improves survival in lung cancer in trial; Blue Cross Blue Shield partners with Lyft; Lilly to submit migraine drug to FDA

Five things for pharma marketers to know: Thursday, May 11, 2017

Five things for pharma marketers to know: Thursday, May 11, 2017

FDA approves Merck/Lilly combo for lung cancer; new PhRMA requirements result in expulsion of 22 members; Pfizer to pay Sangamo $7 million for gene therapy programs

JUICE vet Robert Palmer joins HCB Health as chief innovation officer

JUICE vet Robert Palmer joins HCB Health as chief innovation officer

Palmer spent seven years at JUICE and was a managing partner.

INC Research to buy inVentiv Health in $4.6 billion deal

INC Research to buy inVentiv Health in $4.6 billion deal

The deal will create one of the three biggest contract research organizations in the world.

Study: One-third of new drugs report safety issues

Study: One-third of new drugs report safety issues

Drugs approved through the accelerated approval pathway, as well as psychiatric drugs, were more likely to have a safety issue following FDA approval.

Five things for pharma marketers to know: Wednesday, May 10, 2017

Five things for pharma marketers to know: Wednesday, May 10, 2017

The Senate confirms Gottlieb as FDA commissioner; Endo shares DTC plans for Xiaflex; an AstraZeneca asthma drug fails in late-stage study

CVS relies on personalization in its ExtraCare loyalty program

CVS relies on personalization in its ExtraCare loyalty program

CVS has a pharmacy text program to remind patients to refill their prescriptions and alert them when their medications are ready.

Five things for pharma marketers to know: Tuesday, May 9, 2017

Five things for pharma marketers to know: Tuesday, May 9, 2017

Sanofi ties price increases to growth rate; Regeneron to target 7,000 docs on new eczema drug Dupixent; NIH and biotech execs meet White House officials

How Truth Initiative grew an online community

How Truth Initiative grew an online community

The community manager of the smoking-prevention nonprofit reveals the key ways he drives engagement among online community members

Read the complete 2017 Game Changers digital edition

Read the complete 2017 Game Changers digital edition

Here you'll find Sara Holoubek's deep dive into how pharma is tackling some of its biggest challenges.

As sensitivities rise, the diversity officer's role expands

As sensitivities rise, the diversity officer's role expands

In the wake of high-profile brand flops, everyone from clients to creative teams seeks the counsel of experts.

J&J's Joaquin Duato: Diversity is 'essential'

J&J's Joaquin Duato: Diversity is 'essential'

Under Duato, the leadership team for Johnson & Johnson's pharma group includes six women. "We don't just talk about it," he says.

Five things for pharma marketers to know: Monday, May 8, 2017

Five things for pharma marketers to know: Monday, May 8, 2017

Pfizer to provide Ibrance for free during NICE analysis; the FDA approves new ALS drug; people turn to Twitter to tell stories about pre-existing conditions

Pharma must radically rethink its engagement with doctors

Pharma must radically rethink its engagement with doctors

Amidst the massive technological and social changes upending the societal status quo, the culture of doctors around the globe is also in flux. Technology must be humanized to advance care. McCann Health's "Truth About Doctors" study uncovers what this means for pharma marketers and how the industry can help doctors future-proof their profession.

Five things for pharma marketers to know: Friday, May 5, 2017

Five things for pharma marketers to know: Friday, May 5, 2017

CVS formulary changes lifted Tresiba sales; Novartis licenses NASH drug; FDA is building digital health unit

Bayer's Claritin campaign encourages time outdoors

Bayer's Claritin campaign encourages time outdoors

Claritin is fighting the "indoor epidemic" with its Be an Outsider campaign

Five things for pharma marketers to know: Thursday, May 4, 2017

Five things for pharma marketers to know: Thursday, May 4, 2017

Louisiana may use 1910 law to discount hep-C drugs; House bill would reduce coverage for 24 million people; drugmakers pursue pay-for-performance deals

Klick Health appoints FCB veteran as chief medical officer

Klick Health appoints FCB veteran as chief medical officer

Holly Henry, previously chief medical officer at FCB Health, will oversee medical strategy in the newly created role.

U.S. drug spend grew by 6% in 2016, the lowest rate in two years

U.S. drug spend grew by 6% in 2016, the lowest rate in two years

This is likely due to fewer product launches and lower price increases.

Gilead slowly rolls out ads for Truvada for PrEP — 4 years after approval

Gilead slowly rolls out ads for Truvada for PrEP — 4 years after approval

The drugmaker is is using Tumblr, Snapchat, and YouTube as well as gay dating apps like Grindr to promote its HIV prevention pill.

Five things for pharma marketers to know: Wednesday, May, 3, 2017

Five things for pharma marketers to know: Wednesday, May, 3, 2017

Teaching hospitals that limit detailing prescribe fewer branded drugs; new ad campaign criticizes drug pricing; Ad Age reports healthcare is fastest growing agency discipline

15 years later, a blind man sees his wedding, thanks to VR

15 years later, a blind man sees his wedding, thanks to VR

To demonstrate the power of goggles equipped with AR and VR, the assistive technology company recreated the event on Facebook Live this weekend.

Study: How brands should market to first-time parents

Study: How brands should market to first-time parents

Ketchum, which launched a parent specialty unit, surveyed 400 first-time parents to find out what brands are doing well and how they can do better.

Five things for pharma marketers to know: Tuesday, May 2, 2017

Five things for pharma marketers to know: Tuesday, May 2, 2017

Sales of Merck's Keytruda double in the first quarter; the FDA approves AstraZeneca's immunotherapy; Lilly's insulin is under investigation in two states

Admetsys wins the 2017 MM&M Startup Showdown

Admetsys wins the 2017 MM&M Startup Showdown

The artificial pancreas can provide value to the health system.

Value-based care requires innovators to challenge the status quo

Value-based care requires innovators to challenge the status quo

Execs stressed the importance of collaboration, consumer-mindedness.

Merck, Takeda execs: Is AI the new bad app?

Merck, Takeda execs: Is AI the new bad app?

One executive referred to AI as a "black box" and as the "Tower of Babel."

Pharma faces its 'oh, shit' moment

Pharma faces its 'oh, shit' moment

In his keynote address at the MM&M Transforming Healthcare conference, Dr. Gautam Gulati says the industry is being outpaced by its innovation.

Five things for pharma marketers to know: Monday, May 1, 2017

Five things for pharma marketers to know: Monday, May 1, 2017

The FDA approves osteoporosis drug; groups warn that latest healthcare bill would cut protections for pre-existing conditions; Dupixent gets PBM coverage

4 reasons why patients don't fill their prescriptions

4 reasons why patients don't fill their prescriptions

Researchers still don't know why Americans who are prescribed a prescription drug to treat a chronic condition or disease so often fail to fill those prescriptions.

Day 2 at Health Datapalooza

Day 2 at Health Datapalooza

The market for health data and technology is growing, but the industry must also address concerns about privacy, standards, and diversity.

Day 1 at Health Datapalooza

Day 1 at Health Datapalooza

HHS Secretary Tom Price calls for health IT that works for clinicians and better interoperability.

Five things for pharma marketers to know: Friday, April 28, 2017

Five things for pharma marketers to know: Friday, April 28, 2017

Express Scripts-Anthem deal highlights profitability for PBMs; Sarepta CEO steps down; study says NHS cancer drug fund was ineffective

Amgen, Sandoz argue biosimilar patent case to the Supreme Court

Amgen, Sandoz argue biosimilar patent case to the Supreme Court

Sandoz counsel argued that Amgen's position "wrongly delays the marketing of every biosimilar."

Five things for pharma marketers to know: Thursday, April 27, 2017

Five things for pharma marketers to know: Thursday, April 27, 2017

Novartis, Kaiser, and Qualcomm partner on heart-failure pilot; Novartis and GSK disclose DTC plans; cancer-treatment hype can be negative for patients

Five things for pharma marketers to know: Wednesday, April 26, 2017

Five things for pharma marketers to know: Wednesday, April 26, 2017

GSK warns Advair generic competition may affect business in 2017; Lilly plans to meet FDA about baricitinib; FDA warns companies selling 'illegal' products